Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is a Predictor of Endothelial Function
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Advanced glycation end products (AGEs) and their specific receptor, the receptor for AGEs (RAGE), play an important role in atherosclerosis. Recently, a soluble form of RAGE (sRAGE) has been identified in human serum. However, the role of sRAGE in cardiovascular disease is still controversial. There is no information on the association between simultaneous measurements of AGEs and sRAGE and vascular function. In this study, we evaluated the associations between serum levels of AGEs and sRAGE, ratio of AGEs to sRAGE, and vascular function. RESEARCH DESIGN AND METHODS: We measured serum levels of AGEs and sRAGE and assessed vascular function by measurement of flow-mediated vasodilation (FMD) and nitroglycerine-induced vasodilation in 110 subjects who underwent health examinations. Multivariate regression analyses were performed to identify factors associated with vascular function. RESULTS: Univariate regression analysis revealed that FMD correlated with age, BMI, systolic blood pressure, diastolic blood pressure, heart rate, triglycerides, HDL cholesterol, glucose, smoking pack-years, nitroglycerine-induced vasodilation, serum levels of AGEs and sRAGE, and ratio of AGEs to sRAGE. Multivariate analysis revealed that the ratio of AGEs to sRAGE remained an independent predictor of FMD, while serum level of AGEs alone or sRAGE alone was not associated with FMD. CONCLUSIONS: These findings suggest that sRAGE may have a counterregulatory mechanism that is activated to counteract the vasotoxic effect of the AGE–RAGE axis. The ratio of AGEs to sRAGE may be a new chemical biomarker of endothelial function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter, D. J., Miller, O. I., Sullivan, I. D., Lloyd, J. K., & Deanfield, J. E. (1992) · The Lancet · doi:10.1016/0140-6736(92)93147-f · Cited by 4,742
Endothelial Function: Cardiac Events
Lerman, A., & Zeiher, A. M. (2005) · Circulation · doi:10.1161/01.cir.0000153339.27064.14 · Cited by 1,096
Cited by
Targeting vascular (endothelial) dysfunction
Daiber, A., Steven, S., Weber, A., Shuvaev, V. V., Muzykantov, V. R., Laher, I., Li, H., Lamas, S., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13517 · Cited by 501
“Advanced glycosylation end products (AGEs) and their specific receptor (advanced glycosylation end product-specific receptor [RAGE]), play an important role in atherosclerosis and determine endothelial function in diabetic patients (Kajikawa et al., 2015).”
BackgroundPerrone, A., Giovino, A., Benny, J., & Martinelli, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3818196 · Cited by 459
Sakasai-Sakai, A., Takata, T., Takino, J.-I., & Takeuchi, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14711-3 · Cited by 46
Self-citationRole of ligands of receptor for advanced glycation end products (RAGE) in peripheral artery disease
Yamagishi, S.-I., & Matsui, T. (2018) · Rejuvenation Research · doi:10.1089/rej.2017.2025 · Cited by 31
Self-citationLiu, J., Mao, J., Jiang, Y., Xia, L., Mao, L., Wu, Y., Ma, P., & Fang, B. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-015-1925-3 · Cited by 30
Metadata
- Authors
- Kajikawa, M., Nakashima, A., Fujimura, N., Maruhashi, T., Iwamoto, Y., Iwamoto, A., Matsumoto, T., Oda, N., Hidaka, T., Kihara, Y., Chayama, K., Goto, C., Aibara, Y., Noma, K., Takeuchi, M., Matsui, T., Yamagishi, S.-I., & Higashi, Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-10-21
- Volume
- 38
- Issue
- 1
- Pages
- 119-125
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2047724792
- Cited by
- 104
- References
- 2
- FWCI
- 8.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.